4.7 Article

Melatonin relieves hepatic lipid dysmetabolism caused by aging via modifying the secondary bile acid pattern of gut microbes

Journal

CELLULAR AND MOLECULAR LIFE SCIENCES
Volume 79, Issue 10, Pages -

Publisher

SPRINGER BASEL AG
DOI: 10.1007/s00018-022-04412-0

Keywords

Melatonin; Lipid metabolism; Gut microbiota; Bile acids; FXR

Funding

  1. National Key Research and Development Program of China [2021YF1000602]
  2. Key Research and Development Projects in Shaanxi province [2021NY-020]
  3. Natural Science Foundation of China [U1804106]
  4. Qinghai Fundamental Scientific and Technological Research Plan [2018-ZJ-721]
  5. Scientific Research Guiding Plan Topic of Qinghai Hygiene Department [2018-wjzdx-131]

Ask authors/readers for more resources

It has been reported that aging-induced changes in the gut microbiota may promote hepatic lipid dysmetabolism by shaping the pattern of secondary bile acids. Melatonin treatment reverses these effects and inhibits the expression of hepatic FXR, leading to a decrease in hepatic TMAO production and relief of hepatic lipid dysmetabolism.
It has been reported that aging-generated gut microecosystem may promote host hepatic lipid dysmetabolism through shaping the pattern of secondary bile acids (BAs). Then as an oral drug, melatonin (Mel)-mediated beneficial efforts on the communication between gut microbiota and aging host are still not clearly. Here, we show that aging significantly shapes the pattern of gut microbiota and BAs, whereas Mel treatment reverses these phenotypes (P < 0.05), which is identified to depend on the existence of gut microbiota. Mechanistically, aging-triggered high-level expression of ileac farnesoid X receptor (FXR) is significantly decreased through Mel-mediated inhibition on Campylobacter jejuni (C. jejuni)-induced deconjugation of tauroursodeoxycholic acid (TUDCA) and glycoursodeoxycholic acid (GUDCA) (P < 0.05). The aging-induced high-level of serum taurine chenodeoxycholic acid (TCDCA) activate trimethylamine-N-oxide (TMAO)-triggered activating transcriptional factor 4 (ATF4) signaling via hepatic FXR, which further regulates hepatic BAs metabolism, whereas TUDCA inhibits aging-triggered high-level of hepatic ATF4. Overall, Mel reduces C. jejuni-mediated deconjugation of TUDCA to inhibit aging-triggered high-level expression of hepatic FXR, which further decreases hepatic TMAO production, to relieve hepatic lipid dysmetabolism.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available